MARKET

BHVN

BHVN

Biohaven
NYSE
11.74
+2.12
+22.04%
After Hours: 11.50 -0.24 -2.04% 19:59 01/07 EST
OPEN
9.68
PREV CLOSE
9.62
HIGH
12.05
LOW
9.68
VOLUME
6.71M
TURNOVER
--
52 WEEK HIGH
44.28
52 WEEK LOW
7.48
MARKET CAP
1.56B
P/E (TTM)
-1.5454
1D
5D
1M
3M
1Y
5Y
1D
Biohaven Announces $125 Million Targeted Equity Financing
TipRanks · 1d ago
Biohaven to sell 12.5M shares to Janus Henderson for $125M gross proceeds
Seeking Alpha · 1d ago
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Barchart · 1d ago
Weekly Report: what happened at BHVN last week (1229-0102)?
Weekly Report · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN)
TipRanks · 12/29/2025 11:10
Weekly Report: what happened at BHVN last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Analysts Conflicted on These Healthcare Names: Xenon (XENE) and Biohaven Ltd. (BHVN)
TipRanks · 12/26/2025 18:30
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
Seeking Alpha · 12/26/2025 14:24
More
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Webull offers Biohaven Ltd stock information, including NYSE: BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.